Announcement • Jan 08

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, Its Next AP3-Enabled Development Candidate, Targeting CDK11

Acrivon Therapeutics, Inc. announced significant progress across its pipeline, including updates regarding the Phase 2 ACR-368 program, initial clinical data from the ACR-2316 Phase 1 study, and the nomination of Acrivon’s next AP3-enabled preclinical development candidate, ACR-6840, a potential first-in-class, oral CDK11 inhibitor. With respect to ACR-368, a potential first-in-class CHK1 /CHK2 inhibitor, in Arm 1 of the ACR-368 Phase 2b registrational-intent trial (monotherapy BM+ subjects), an updated interim analysis (EDC data extract as of December 4, 2025) showed an ORR of 39%, and in subjects with =2 prior lines of therapy the ORR was 44%. Based on data showing higher response rates in subjects with serous endometrial cancer across Arm 1 and Arm 2 (ACR-368 with ULDG in BM- subjects), Arm 3 will now focus exclusively on subjects with serous cancer and =2 prior lines of therapy, with updated interim analysis showing a cORR of 67% in BM+ subjects (N=12) with serous EC and an interim analysis across both BM+ and BM- subjects showing a cORR of 52% (N=23) in serous subjects versus 22% (N=37) in non-serous EC subjects, all of whom received up to two prior lines of therapy including chemotherapy and anti-PD-1. Consistent with the higher cORR observed across all subjects with serous EC, BM levels were overall higher in this tumor type, and these results are consistent with serous tumors often being G1-S-deficient, leading to DNA damage repair stress and dependency on the G2-M checkpoint controlled by CHK1/CHK2. The EU Clinical Trial Application for Arm 3 of the ongoing US multicenter, registrational-intent Phase 2b trial in serous subjects with =2 prior lines of therapy and without requirement for a tumor biopsy has been submitted, with more than 20 sites selected across Germany, Italy, France and Spain, and initial patient enrollment in the EU is expected in the first quarter of 2026 while enrollment continues at previously activated US clinical sites. Arm 3 evaluates ACR-368 combined with ULDG as a sensitizer in BM-unselected subjects with serous EC who have received up to two prior lines of therapy without requirement for a tumor biopsy, and the company expects to complete enrollment in Arm 3 in the fourth quarter of 2026, with a design of up to 90 subjects and potential validation of clinical significance in as few as 40 subjects, including the possibility of earlier interim analysis. On November 12, 2025, after incorporating feedback from a Type B meeting with the FDA earlier in 2025 and based on strong rationale and preclinical studies demonstrating synergy between ACR-368 and anti-PD-L1, the company submitted the proposed protocol design for a planned Phase 3 confirmatory study evaluating ACR-368 in combination with an anti-PD-1 agent in frontline advanced or recurrent pMMR EC subjects, and no further feedback has been received from the FDA. Regarding ACR-2316, a potential first-in-class WEE1 /PKMYT1 inhibitor, a total of 33 patients were dosed across two weekly oral dosing schedules in the ongoing Phase 1 monotherapy dose-escalation study (EDC data extract as of December 22, 2025), and initial clinical data successfully established two weekly oral dosing regimens of 160 mg QD on a 3-day on /4-day off schedule and 240 mg QD on a 2-day on /5-day off weekly schedule, with a favorable tolerability profile and transient, mechanism-based hematological adverse events predominantly neutropenia. A cohort aiming to establish a bi-weekly 2-day on /12-day off dosing regimen has been initiated based on projected enhanced single-agent activity and to provide further dosing flexibility for potential future combination studies, with clinical activity observed at dose levels of 120 mg and above, including tumor shrinkage in 9 out of 20 evaluable patients, a confirmed partial response in a subject with EC, and unconfirmed partial responses in subjects with SCLC and squamous NSCLC. Details include a subject with high-grade Mullerian EC (BRCA1/2 wild type) enrolled at 120 mg who achieved a confirmed partial response and remained on therapy for 42 weeks, a subject with SCLC enrolled at 160 mg who achieved an unconfirmed partial response with initial 50% tumor shrinkage and subsequent 69% shrinkage of the target lesion, and a subject with squamous NSCLC enrolled at 240 mg and reduced to 200 mg who achieved an unconfirmed partial response later confirmed. The trial continues to focus on selected, AP3-prioritized solid tumor types. With respect to ACR-6840, a potential first-in-class CDK11 inhibitor, the compound has been nominated as the next development candidate from the company’s AP3-driven cell cycle program, with several promising back-up series identified; CDK11 is described as a challenging but compelling target with multiple isoforms and broad cell cycle regulatory roles, and ACR-6840 was rationally designed using the AP3 platform to achieve optimal on-target pathway effects, with IND submission anticipated in the fourth quarter of 2026. Anticipated upcoming milestones include initiating EU enrollment for Arm 3 of the ACR-368 Phase 2 trial in the first quarter of 2026, providing additional updates on Arm 1 and initial clinical data from Arm 3 in mid-2026, achieving readiness for a Phase 3 confirmatory trial for ACR-368 in combination with PD-1 therapy in mid-2026, completing enrollment in the biopsy-independent Phase 2 Arm 3 trial in the fourth quarter of 2026, reporting additional ACR-2316 Phase 1 clinical data and transitioning into dose expansion in the first half of 2026, submitting an IND for ACR-6840 in the fourth quarter of 2026, and initiating additional internal programs utilizing the AP3 platform in the second half of 2026. As of December 31, 2025, the company had preliminary, unaudited cash, cash equivalents and investments of approximately $119 million, expected to fund operating expenses and capital expenditure requirements into the second quarter of 2027, noting that these amounts are preliminary and subject to completion of financial closing procedures and may differ materially from amounts reflected in the company’s consolidated financial statements for the quarter and year ended December 31, 2025.

Announcement • Sep 14

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2

Acrivon Therapeutics, Inc. presented additional positive clinical data at ESMO from the ongoing registrational intent, multicenter Phase 2 trial of ACR-368 in patients with locally advanced or metastatic, recurrent endometrial cancer. The company has also disclosed that the Investigational New Drug (IND) application for its next clinical candidate, ACR-2316, has been cleared by the FDA with initial clinical sites now activated, and first-in-human dosing for the Phase 1 study expected in the fourth quarter of 2024. ACR-368 Updates and Highlights: Presented data at ESMO from the ongoing, registrational-intent, multicenter Phase 2 trial of ACR-368 in patients with high grade endometrial cancer. Importantly, all patients enrolled must have progressed on prior anti-PD-1 therapy, unless ineligible. The data were based on 35 safety-evaluable subjects, of which 23 (8 BM+ and 15 BM-) were efficacy-evaluable with at least one on-treatment scan (data cut off July 25, 2024). Reported a confirmed ORR (RECIST 1.1) of 62.5% (95% CI, 30.4-86.5) observed in the cohort of prospectively-selected OncoSignature-positive (BM+) patients who were efficacy-evaluable. Endometrial cancer is a tumor type that was predicted to be sensitive to ACR-368 by AP3-enabled indication screening before any clinical data was generated. Median duration of response (mDOR) was not yet reached (~6 months at time of data cut-off); all responding patients still on therapy Best overall response (BOR) in last prior line predominantly progressive disease (PD) in confirmed ACR-368 responders. Confirmed responses were observed across molecular and histological subtypes. Demonstrated the ability of the AP3-based ACR-368 OncoSignature assay to prospectively predict patients sensitive to ACR-368 monotherapy based on updated data that showed a clear segregation of responders in the BM+ versus OncoSignature-negative (BM-) arms (p-value = 0.009). Observed further evidence of sensitization to ACR-368 by ultra-low dose gemcitabine (ULDG) in a proportion of BM- subjects, with an initial disease control in 8 out of 15 subjects, including 1 confirmed complete response (CR) Consistent with past trials and earlier reported data from this trial, the ACR-368 treatment-related adverse events observed were limited, predominantly transient, reversible, mechanism-based hematological AEs, which typically occurred during the first 1-2 cycles of therapy. There was a notable absence of long-lasting myelosuppression, or the typical more severe non-hematological AEs commonly seen with ADCs and chemotherapy. Company conducted a blinded third-party KOL market research study which showed strong interest in the emerging clinical profile of ACR-368 (product name blinded) as an important potential therapy in the rapidly evolving treatment landscape of endometrial cancer where second line options are now limited due to anti-PD-1 and chemotherapy having been approved in front line therapy An estimated ~30K new cases of high-grade, locally advanced or metastatic, recurrent (progressed on anti-PD-1 and chemotherapy) endometrial cancer per year. ~90% of these patients will progress to second line. The recent approval of pembrolizumab plus chemotherapy as a first-line treatment leaves a significant unmet need in the second-line, where the bar from reported chemotherapy efficacy in second-line is an ORR of 14.7% and mPFS of 3.8 months (Makker et al; N Engl J Medicine, 2022). ACR-2316 Updates: The company today disclosed that the FDA has cleared the IND for its novel, dual WEE1/PKMYT1 inhibitor ACR-2316, ahead of projected timelines. Multiple clinical sites have been activated for the Phase 1 dose optimization study. Initial patient dosing expected in fourth quarter 2024 in selected tumor types. AP3 Interactome Updates: Proprietary, computational analytics platform leveraging machine learning now further advanced for integrated comprehensive analyses across all large, in-house AP3 phosphoproteomic drug profiling data sets. Integration enables quantitative analyses to generate actionable insights for rational drug design, predictive biomarkers, resistance mechanisms, and indication finding to be implemented in the clinic. AP3 Interactome has been deployed to enable indication finding and patient responder identification for ACR-368 and to generate the novel dual WEE1/PKMYT1 inhibitor ACR-2316.

Total Shareholder Yield	0.5%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Segment	Dividend Yield
Company (ACRV)	n/a
Market Bottom 25% (US)	1.4%
Market Top 25% (US)	4.1%
Industry Average (Biotechs)	2.2%
Analyst forecast (ACRV) (up to 3 years)	n/a

Data	Last Updated (UTC time)
Company Analysis	2026/07/15 23:42
End of Day Share Price	2026/07/15 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

Analyst	Institution
Li Wang Watsek	Cantor Fitzgerald & Co.
Silvan Tuerkcan	Citizens JMP Securities, LLC
Emily Bodnar	H.C. Wainwright & Co.

Acrivon Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Acrivon Therapeutics: Priced For Failure, Built For Precision

Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely?

Acrivon Therapeutics, Inc., Annual General Meeting, Jun 17, 2026

Acrivon Therapeutics Inc Highlights Preclinical Data with Three Posters At Aacr Demonstrating Strong Acr-368 and Acr-2316 Synergies with Immune Checkpoint Inhibitors and Adc Payloads

We're Keeping An Eye On Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, Its Next AP3-Enabled Development Candidate, Targeting CDK11

Acrivon Therapeutics, Inc. to Announce Clinical Update on Its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates

Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely?

Acrivon Therapeutics, Inc.(NasdaqGM:ACRV) dropped from Russell 2000 Dynamic Index

Acrivon Therapeutics, Inc., Annual General Meeting, Jun 13, 2025

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Acrivon Therapeutics, Inc. Announces Chief Medical Officer Changes , Effective April 9, 2025

We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

Acrivon Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective as of April 1, 2025

Acrivon Therapeutics, Inc. Announces FDA Grants Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate

Acrivon Therapeutics, Inc. Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2

Is Acrivon Therapeutics (NASDAQ:ACRV) In A Good Position To Invest In Growth?

New major risk - Revenue and earnings growth

Acrivon Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Price target increased by 13% to US$21.00

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress At Corporate R&D Event

New major risk - Share price stability

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation

Acrivon Therapeutics, Inc. Appoints Santhosh Palani to its Board of Directors

New major risk - Revenue and earnings growth

Acrivon Therapeutics, Inc. Appoints Ivana Magovcevic-Liebisch to its Board of Directors

New minor risk - Market cap size

Price target decreased by 7.1% to US$20.43

Acrivon Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer

New minor risk - Share price stability

New minor risk - Market cap size

Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Acrivon Therapeutics, Inc. Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Acrivon Therapeutics Announces the Appointment of Adam Levy as Senior Vice President and Head, Investor Relations and Corporate Affairs

Acrivon Therapeutics, Inc. Appoints Charles (Chuck) Baum as Board of Directors

Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans

Co-Founder exercised options to buy US$416k worth of stock.

Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer

We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth

High number of new and inexperienced directors

Acrivon Therapeutics, Inc. has completed an IPO in the amount of $94.375 million.

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources